Clinical Best Practices for Radiation Safety During an Alpha DaRT Treatment.

Alpha DaRT is a new alpha radiation treatment for treating solid tumors and is currently being evaluated through clinical trials worldwide. Being a novel radiation treatment, it is important to discuss the safety considerations and procedures that are needed to ensure safe use of this unique approach. The objective of this article is to provide a set of recommendations-radiation safety best practices that were developed based on operational and clinical experience.

'Taking it one day at a time' and 'Reaching back out to help someone': How transgender women living with HIV and community stakeholders navigate violence, oppression, and health through coping and advocacy.

Background: Transgender women living with HIV face intersectional oppression resulting in consequences for their mental and physical health. Interventions are needed that center the voices of transgender women living with HIV (TWLWH) and community stakeholders engrossed in work on behalf of the transgender community through advocacy and/or work roles.

Methods: Through a partnership with a trans led and focused program of a community-based health organization and an academic partner, from October 2020 through October 2021, TWLWH and community stakeholders participated in qualitative interviews on trauma, violence, mental health struggles, HIV stigma, gender discrimination, health behaviors (e.

Utilising integrated bio-behavioural surveillance (IBBS) to investigate declining hepatitis C antibody prevalence among people who inject drugs in the Australian Needle and Syringe Program Survey.

Background: Prevalence of hepatitis C virus (HCV) antibody (Ab) on dried blood spot (DBS) samples in the Australian Needle and Syringe Program Survey (ANSPS) decreased nationally from 57 % in 2015 to 32 % in 2022. We aimed to investigate potential explanations for this decline.

Methods: Changes in DBS HCV Ab prevalence were investigated by redefining positive cases as those with those with either a positive HCV Ab test result or a self-reported history of ever having HCV treatment (modified prevalence), examining HCV Ab prevalence by birth and age cohorts, and assessing trends in key risk behaviours.

Utilising Integrated Bio-behavioural Surveillance (IBBS) to investigate declining hepatitis C antibody prevalence among people who inject drugs in the Australian Needle and Syringe Program Survey.

Background: Prevalence of hepatitis C virus (HCV) antibody (Ab) on dried blood spot (DBS) samples in the Australian Needle and Syringe Program Survey (ANSPS) decreased nationally from 57% in 2015 to 32% in 2022. We aimed to investigate potential explanations for this decline.

Methods: Changes in DBS HCV Ab prevalence were investigated by redefining positive cases as those with those with either a positive HCV Ab test result or a self-reported history of ever having HCV treatment (modified prevalence), examining HCV Ab prevalence by birth and age cohorts, and assessing trends in key risk behaviours.

Estimation of kidney doses from [Lu]Lu-DOTA-TATE PRRT using single time point post-treatment SPECT/CT.

Background: Dosimetry after [Lu]Lu-DOTA-TATE therapy can be demanding for both patients and the clinical service due to the need for imaging at several time points. In this work we compare three methods of single time point (STP) kidney dosimetry after [Lu]Lu-DOTA-TATE therapy with a multiple time point (MTP) dosimetry method.

Method: Method 1 (MTP): Kidney doses were calculated from 31 patients including 107 therapy cycles.